This inventor holds 5 USPTO granted patents and 4 published patent applications. Top assignees: Trillium Therapeutics Inc., Veritas Therapeutics Inc., Transplantation Technologies Inc.. Active years: 2002-2022.
Company Filing History:
2 out of 29 
2 out of 2 
1 out of 2 Years Active: 2002-2022
Title: Gary Levy: Innovator in Cancer Treatment
Introduction
Gary Levy is a prominent inventor based in Thornhill, CA, known for his significant contributions to the field of cancer treatment. With a total of five patents to his name, Levy has focused on developing innovative solutions that address critical health challenges.
Latest Patents
Among his latest patents are the FGL2 antibodies and binding fragments thereof, which are specifically designed to bind FGL2. This disclosure highlights the potential uses of these antibodies and binding fragments in treating cancer. Another notable patent involves the use of soluble FGL2 as an immunosuppressant. This patent outlines methods and compositions for inducing immune suppression, which can be beneficial in preventing graft rejection, autoimmune diseases, and allergies.
Career Highlights
Throughout his career, Gary Levy has worked with several notable companies, including Veritas Therapeutics Inc. and Trillium Therapeutics Inc. His work in these organizations has contributed to advancements in therapeutic approaches for various medical conditions.
Collaborations
Levy has collaborated with esteemed colleagues such as David A. Clark and Philip Marsden, further enhancing the impact of his research and innovations.
Conclusion
Gary Levy's work exemplifies the spirit of innovation in the medical field, particularly in cancer treatment and immune suppression. His patents reflect a commitment to improving patient outcomes through scientific advancements.